You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Med., 26 July 2023

Sec. Gastroenterology

Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1256685

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

  • 1. Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

  • 2. Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Article metrics

View details

1

Citations

867

Views

374

Downloads

In the published article, the author names were incorrectly written as “Ning Yan, Zi Zhang, San Guo, Shu Shen, Xing Li”. The correct spellings are “Ningning Yan, Ziheng Zhang, Sanxing Guo, Shujing Shen, Xingya Li”.

In the published article, there was a mistake in the Author contributions. The correct Author contributions appears below.

Statements

Author contributions

NNY, ZHZ, SJS, and XYL wrote the manuscript. NNY, ZHZ, and SXG prepared Figures and Tables. All authors have reviewed the manuscript and gave their consent to publication. All authors contributed to the article and approved the submitted version.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

liver cancer, tyrosine kinase inhibitors, MET, savolitinib, MET-TKI

Citation

Yan N, Zhang Z, Guo S, Shen S and Li X (2023) Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report. Front. Med. 10:1256685. doi: 10.3389/fmed.2023.1256685

Received

11 July 2023

Accepted

13 July 2023

Published

26 July 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

10 - 2023

Updates

Copyright

*Correspondence: Shujing Shen Xingya Li

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics